A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity.
Rift Valley fever virus (RVFV) has been cited as a potential biological-weapon threat due to the serious and fatal disease it causes in humans and animals and the fact that this mosquito-borne virus can be lethal in an aerosolized form. Current human and veterinary vaccines against RVFV, however, are outdated, inefficient, and unsafe. We have incorporated the RVFV glycoprotein genes into a nonreplicating complex adenovirus (CAdVax) vector platform to develop a novel RVFV vaccine. Mice vaccinated with the CAdVax-based vaccine produced potent humoral immune responses and were protected against lethal RVFV infection. Additionally, protection was elicited in mice despite preexisting immunity to the adenovirus vector.
Holman
David H
DH
GenPhar, Inc., Division of Biodefense Vaccines, 600 Seacoast Pkwy., Mount Pleasant, South Carolina 29464, USA.
Penn-Nicholson
Adam
A
Wang
Danher
D
Woraratanadharm
Jan
J
Harr
Mary-Katherine
MK
Luo
Min
M
Maher
Ellen M
EM
Holbrook
Michael R
MR
Dong
John Y
JY
D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D005822:Genetic Vectors; D008297:Male; D051379:Mice; D012295:Rift Valley Fever / Q000276:immunology / Q000517:prevention & control*; D012296:Rift Valley fever virus / Q000235:genetics / Q000276:immunology*; D016019:Survival Analysis; D015678:Viral Structural Proteins / Q000235:genetics / Q000276:immunology; D014765:Viral Vaccines / Q000235:genetics / Q000276:immunology*
D000914:Antibodies, Viral; D015678:Viral Structural Proteins; D014765:Viral Vaccines